Ligand validation:3WN4

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 3WN4 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3WN4_NAG_A_902	95%	40%	0.057	0.96	0.85	1.46	-	3	1	0	100%	0.9333
3WN4_NAG_A_920	87%	20%	0.078	0.949	1.02	2.3	1	7	0	0	100%	0.9333
3WN4_NAG_A_910	70%	51%	0.129	0.948	0.86	1.02	-	1	0	0	100%	0.9333
3WN4_NAG_A_915	51%	16%	0.167	0.92	1.18	2.51	1	7	0	0	100%	0.9333
3WN4_NAG_A_903	48%	53%	0.184	0.928	0.8	1	-	1	0	0	100%	0.9333
3WN4_NAG_A_916	35%	33%	0.225	0.913	0.72	1.91	-	3	0	0	100%	0.9333
3WN4_NAG_A_921	29%	15%	0.191	0.849	1.1	2.62	1	8	0	0	100%	0.9333
3WN4_NAG_A_911	19%	43%	0.273	0.869	0.44	1.73	-	4	1	0	100%	0.9333
3WN4_NAG_A_904	18%	19%	0.222	0.811	0.61	2.75	-	10	2	0	100%	0.9333
4R0A_NAG_A_917	95%	19%	0.059	0.96	1.39	2.05	2	4	1	0	100%	0.9333
5WYX_NAG_A_914	94%	35%	0.059	0.957	0.85	1.7	-	3	0	0	100%	0.9333
4QC0_NAG_A_905	93%	53%	0.058	0.954	0.52	1.27	-	2	0	0	100%	0.9333
3W3L_NAG_A_1016	87%	54%	0.065	0.937	0.56	1.19	-	2	0	0	100%	0.9333
5AWA_NAG_A_914	86%	42%	0.09	0.96	1.06	1.19	1	2	0	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3PPS_NAG_B_760	100%	44%	0.028	0.993	0.57	1.57	-	3	0	0	100%	0.9333
5O59_NAG_A_601	100%	70%	0.024	0.993	0.3	0.85	-	-	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.